News & Updates

Show Multimedia Only
Fluvoxamine wins, metformin disappoints in long COVID fatigue
Fluvoxamine wins, metformin disappoints in long COVID fatigue
a day ago byElvira Manzano

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue
a day ago
Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
18 Jun 2026 byStephen Padilla

In older or frail patients with stage III non-small cell lung cancer (NSCLC), undergoing reduced radiotherapy (RT) followed by sequential chemo-immunotherapy results in survival outcomes similar to standard RT, indicating its utility in vulnerable populations, suggests a study.

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
18 Jun 2026